Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma
Author:
Affiliation:
1. Duke Cancer Institute, Duke University Medical Center , Durham, NC , USA
2. Sarcoma Oncology Research Center , Santa Monica, CA , USA
3. NanoCarrier Co., Ltd. , Tokyo , Japan
Abstract
Funder
NanoCarrier Co., Ltd.
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Oncology
Link
https://academic.oup.com/oncolo/article-pdf/27/10/809/46284910/oyac155.pdf
Reference5 articles.
1. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study;Penel;J Clin Oncol,2008
2. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group;Nielsen;Br J Cancer,1998
3. Real-world clinical outcomes and prognostic factors for patients with advanced angiosarcoma who received systemic treatment;Park;Cancer Res Treat,2021
4. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials;Young;Eur J Cancer,2014
5. Outcomes of systemic therapy for patients with metastatic angiosarcoma;D’Angelo;Oncology,2015
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Recent advances of polymeric nanoplatforms for cancer treatment: smart delivery systems (SDS), nanotheranostics and multidrug resistance (MDR) inhibition;Biomedical Materials;2023-11-27
2. Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment;Journal of Controlled Release;2023-01
3. Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models;Nature Communications;2022-11-22
4. Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine;International Journal of Molecular Sciences;2022-11-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3